Observation of effect on Entecavir in the treatment of hepatitis B cirrhosis
Yin Jiang
Abstract
Yin Jiang
Abstract
Objective To observe clinical effect of hepatitis B cirrhosis treated with Entecavir.Methods 88 patients with hepatitis B cirrhosis were divided into treatment group(44 patients) and control group(44 patients) randomly.The control group received conventional liver-protecting and symptomatic treatment only,while the treatment group received additional Entecavir(0.5 mg/d,one year course).The liver function,Child-Pugh grade,HBV DNA and liver fibrosis markers(HA,LN,PⅢP and Ⅳ-C) of two groups were observed.Results The total effective rate of treatment group(95.5%) was higher than control group(63.6%)(P 0.01).After treatment,the liver fibrosis markers(HA,LN,PⅢP and Ⅳ-C),liver function and Child-Pugh grade in both groups were significantly improved(P 0.05).There were significant differences of liver fibrosis markers(HA,LN,PⅢP and Ⅳ-C),liver function,Child-Pugh grade and HBV DNA between treatment group and control group after treatment(P 0.05).Conclusion Entecavir has significant clinical effect,low adverse reaction and good tolerance in treating patients with hepatitis B cirrhosis.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To observe clinical effect of hepatitis B cirrhosis treated with Entecavir.Methods 88 patients with hepatitis B cirrhosis were divided into treatment group(44 patients) and control group(44 patients) randomly.The control group received conventional liver-protecting and symptomatic treatment only,while the treatment group received additional Entecavir(0.5 mg/d,one year course).The liver function,Child-Pugh grade,HBV DNA and liver fibrosis markers(HA,LN,PⅢP and Ⅳ-C) of two groups were observed.Results The total effective rate of treatment group(95.5%) was higher than control group(63.6%)(P 0.01).After treatment,the liver fibrosis markers(HA,LN,PⅢP and Ⅳ-C),liver function and Child-Pugh grade in both groups were significantly improved(P 0.05).There were significant differences of liver fibrosis markers(HA,LN,PⅢP and Ⅳ-C),liver function,Child-Pugh grade and HBV DNA between treatment group and control group after treatment(P 0.05).Conclusion Entecavir has significant clinical effect,low adverse reaction and good tolerance in treating patients with hepatitis B cirrhosis.
Key concepts: Entecavir, Medicine, Cirrhosis, Gastroenterology, Internal medicine, Liver function, Hepatitis B, Hepatitis a virus